Home / Health / CAR T Therapy Cures Boy's Liver Cancer
CAR T Therapy Cures Boy's Liver Cancer
22 Nov
Summary
- Experimental CAR T cell therapy achieved complete regression of liver cancer.
- A three-year-old patient showed no signs of disease after treatment.
- This breakthrough offers hope for treating other solid tumors.

A remarkable advancement in cancer treatment has emerged from an early-phase clinical trial, showcasing the potential of CAR T cell therapy against solid tumors. Researchers documented the case of a three-year-old boy diagnosed with aggressive hepatoblastoma, a form of liver cancer. Despite undergoing chemotherapy and surgery, his cancer rapidly recurred and spread to his lungs.
Enrolled in the CARE study, the boy received two infusions of an experimental GPC3-CAR T cell therapy, engineered from his own cells to target liver cancer proteins. Following the initial dose, he showed a partial response, and after the second infusion, scans revealed no signs of disease, only residual scarring.
Twelve months later, the patient remained disease-free, marking a significant victory. This success suggests CAR T cell therapy may be a safe and effective option for hepatoblastoma and warrants further investigation for other GPC3+ solid tumors. The findings, reported in The New England Journal of Medicine, offer immense promise for advancing immunotherapy treatments for liver cancer, which is a leading cause of cancer-related death globally.